Chronic infl ammatory disorders are often associated with an increased risk of developing cancer. A classic example of the connection between infl ammation and cancer is the increased risk of colorectal cancer in patients with infl ammatory bowel disease (IBD). In this review, we discuss aspects of IBD that promote colorectal cancer and highlight key molecular mediators that contribute to cancer risk. Additionally, we report on progress in identifying molecular targets that may prove effi cacious in blocking the progression of IBD-related infl ammation to cancer.
Introduction
Infl ammatory bowel disease (IBD) affects approximately 1.4 million people in the United States. The most common forms of IBD are Crohn's disease (CD) and ulcerative colitis (UC). The primary differences between these diseases are the location and nature of the infl ammatory response. CD can affect any part of the gastrointestinal tract and most commonly affects the terminal ileum, whereas UC is restricted to the colon and/or rectum. Furthermore, CD is characterized by granulomas and transmural infl ammation, whereas UC-related infl ammation is restricted to the mucosa and submucosa. Because of chronic damage to the colon and rectum in both types of IBD, these patients are at an increased risk of colorectal cancer (CRC). This risk is even more pronounced with longer duration of disease and greater extent and severity of colitis [1] [2] [3] . This review explores the relationship between infl ammatory responses in IBD and the pathogenesis of CRC and discusses advances in understanding some of the key molecular culprits.
Chronic Infl ammation in IBD
Chronic infl ammatory responses that occur in IBD have been connected to predisposing genetic factors, which contribute to abnormal immune responses to luminal bacteria [4] . A number of genetic alterations associated with IBD have been identifi ed in genes related to innate and adaptive immune responses. The fi rst gene shown to be associated with CD was NOD2/CARD15, which encodes a protein that acts as an intracellular pattern-recognition receptor for bacterial muramyl dipeptides [5, 6] . Polymorphisms in two autophagy-related genes (ATG16L1 and IRGM) are also associated with CD and are important for degradation and antigen processing of intracellular pathogens [7, 8] . Genes of the adaptive immune system that have been linked to CD and UC include components of the interleukin (IL)-23 signaling pathway, which affect T-cell differentiation. These are IL23R, which encodes a subunit of the receptor for IL-23R; IL12B, which encodes the p40 subunit of IL-12 and IL-23; and STAT3, which encodes signal transducer and activator of transcription 3 [9,10]. A working model for the pathogenesis of IBD is that genetic and environmental factors that predispose individuals to defects in sampling gut luminal antigens lead to activation of innate immune responses. Exacerbated responses to antigens activate dendritic cells, which then mediate differentiation of naive T cells into effector cells [11] . In CD, aberrant immune responses cause a bias toward the production of cytokines associated with a T helper cell 1 (TH 1 ) and TH 17 response. In contrast, UC disease is primarily associated with a TH 2 and natural killer T-cell response [11] . Thus, the chronic activation of these key immune cells and their secreted products contribute to a tissue environment that can culminate in cancer.
Key Players in Infl ammation-Associated CRC
In recent years, several molecules have emerged as critical players in contributing to infl ammation-associated CRC. These culprits have been the focus of intense research to understand the molecular basis of their association with disease and to explore therapeutic possibilities. In this article, we highlight some of these molecules, namely cyclooxygenase-2 (COX-2), nuclear factor-κB (NF-κB), tumor necrosis factor-α (TNF-α), and toll-like receptors (TLRs), describing their connection to infl ammation and cancer and discussing recent advances in elucidating their contribution to disease.
COX-2
COX-2 is an intermediate response gene that encodes a cytoplasmic protein, which catalyzes the synthesis of prostaglandins from arachidonic acid. COX-2 expression is activated by numerous proinfl ammatory cytokines, including IL-1α, IL-1β, and TNF-α, and it is increased at sites of infl ammation [12] . In relation to human cancer, COX-2 is overexpressed in approximately 80% of CRCs and 40% of colorectal adenomas relative to normal mucosa [13] . By immunohistochemistry, COX-2 is found in the cytoplasm of neoplastic colonic epithelial cells and to a lesser extent in stromal cells, whereas normal epithelium is negative for COX-2 [14] . Activation of COX-2 expression in neoplastic cells is also seen in genetic mouse models of intestinal cancer involving mutations in the tumor suppressor adenomatous polyposis coli (Apc) and in rodent models of colon cancer using a combination treatment of azoxymethane (AOM) and dextran sodium sulfate (DSS) to induce infl ammation-associated tumors [14] .
The contribution of COX-2 to the development of CRC is further supported by the fact that coxibs-a class of nonsteroidal anti-infl ammatory drugs that specifi cally target COX-2-are highly effective in reducing colon cancer in rodent models and humans [15, 16] . COX-2 is thought to contribute to tumor development by modulating apoptosis, angiogenesis, and tumor invasiveness. Effects on apoptosis were shown in rat intestinal epithelial cells with ectopic expression of COX-2 [17]. These cells had increased adherence to the extracellular matrix, resistance to apoptosis-inducing agents, and upregulation of the antiapoptotic protein B-cell lymphoma-2 (Bcl-2). Similar results were seen with overexpression of COX-2 in human colon cancer cells in which COX-2 provided resistance to apoptosis following treatment with antineoplastic drugs [18] . In affecting the progression of cancer, COX-2 has been shown to increase invasiveness of colon cancer cells by way of activation of metalloproteinase-2 (MMP-2) [19] . Furthermore, suppression of COX-2 in human prostate tumor cells by a selective COX-2 inhibitor resulted in reduced levels of . In relation to angiogenesis, expression of COX-2 in Caco-2 and HCA-7 colon cancer cells correlated with high levels of vascular endothelial growth factor, basic fi broblast growth factor, and endothelin-1, which stimulate endothelial migration and endothelial tube formation [21] .
Given the extensive role of COX-2 in infl ammation and various aspects of carcinogenesis, COX-2 is an attractive target for treatment of infl ammatory disorders and cancer. A search for COX-2-specifi c inhibitors resulted in promising candidates, such as valdecoxib, celecoxib, and rofecoxib. Indeed, clinical trials with specifi c COX-2 inhibitors showed great promise for treatment of patients with prior adenomas. However, these trials were discontinued because of increased risk of thrombotic events [22••, 23••].
NF-κB
NF-κB is a key regulator of innate immunity and infl ammation, and its constitutive activation is associated with various types of cancer, including acute lymphoblastoid leukemia, Hodgkin's lymphoma, and breast, ovarian, prostate, and colon cancer [24] . NF-κB is a dimeric transcription factor that is composed of members of the Rel transcription factor family, and its activity is directed toward a wide array of genes that promote proliferation and survival [25] . In tumor, epithelial, and immune cells, NF-κB activates the expression of genes encoding infl ammatory cytokines, adhesion molecules, enzymes in the prostaglandin synthesis pathway (including COX-2), inducible nitric oxide synthase, and angiogenic factors [26••] . In addition, NF-κB induces expression of a number of antiapoptotic genes, including Bcl-2 family members, which can provide a survival advantage to precancerous or tumor cells.
In the resting nonstimulated state, NF-κB dimers are cytoplasmic and inactive. Activation of NF-κB occurs downstream from signaling pathways mediated through TLRs and other microorganism-sensing molecules or by the infl ammatory cytokines TNF-α and IL-1β [26••]. The canonical regulation of NF-κB involves sequestration of NF-κB in the cytoplasm by the inhibitor IκB. IκB levels are regulated by the IκB kinase (IKK) complex, which phosphorylates IκB, targeting it for ubiquitin-dependent degradation [27] . Upon the degradation of IκB, NF-κB is released and translocates to the nucleus, where it becomes transcriptionally active. Targets of NF-κB can be separated into four functional categories: antiapoptotic genes, infl ammatory and immunoregulatory genes, genes that promote cell cycle progression, and genes that encode negative regulators of NF-κB. Many of these targets have been associated with cancer initiation and progression [27] .
A seminal article presented by Greten et al. [28] in which NF-κB activity was disrupted in a mouse model of colitis-associated cancer contributes to our understanding of the role of NF-κB in infl ammation-associated carcinogenesis. In this article, the authors developed mice with deletions of IKKβ, a component of the IKK complex, in intestinal epithelial cells or myeloid cells, resulting in functional inactivation of NF-κB in the two cell types. The authors then tested the effects of inactivation of NF-κB in the two cell types by treating the mice with a combination of AOM and DSS to induce infl ammationassociated tumors. When NF-κB activity was disrupted in colonic epithelial cells, there was a dramatic reduction in tumor number in these mice. In examining the mechanism, there was enhanced epithelial cell apoptosis during
